Press Releases

TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the initiation of its Phase 3/

SAN DIEGO and PENNINGTON, N.J., Sept. 26, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company ove

TORRANCE, Calif., Sept. 26, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019. The common stock of Emmaus was previously quoted on OTC Link® as OTC P

NEW YORK, Sept. 26, 2019 /PRNewswire/ -- Hospital for Special Surgery (HSS), the top-ranked orthopedic hospital in the nation, today announced the appointments of Harvinder S. Sandhu, MD, MBA, and Andrew A. Sama, MD, as the new co-chiefs of its spine service, effective October 2019

DULUTH, Ga., Sept. 26, 2019 /PRNewswire/ -- Boehringer Ingelheim, a global leader in veterinary rabies vaccines2, plans to donate 60,000 doses of its IMRAB® rabies vaccine for dogs over the next three years to fight rabies in Puerto Rico.

DODGEVILLE, Wisc., Sept. 26, 2019 /PRNewswire/ -- Lands' End (NASDAQ: LE), the iconic American heritage brand, has launched a new line of scrubs to service the healthcare industry. The line was developed by Lands' End Business, a division of Lands' End specializing in an extensive range of business uniforms, workwear and promotional items, with the unique ability to

MINNEAPOLIS, Sept. 26, 2019 /PRNewswire/ -- Nura announced today that it will begin providing free Narcan® kits and training directly to select patients who take opiat

ABBOTT PARK, Ill., Sept. 26, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Proclaim XR™ recharge-free neurostimulation system for people living with chronic pain. The Proclaim XR platform offers a low dose of Abbott's proprietary BurstDR™ stimulation waveform, which was created based on sc

DALLAS, Sept. 26, 2019 /PRNewswire/ -- Phynd Technologies, Inc., a leading health care provider information management platform, announced that it has joined the

CAMBRIDGE, Mass., Sept. 26, 2019 /PRNewswire/ -- In a new study just published in JCO Clinical Cancer Informatics, researchers from the Massachusetts Ins